ClinicalTrials.gg
CompletedNCT00462345Updated Nov 4, 2014Results posted

A Study of MabThera (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-TNF Therapies.

A Phase 4 interventional study of rituximab and Methotrexate in Rheumatoid Arthritis, sponsored by Hoffmann-La Roche. Completed at 4 sites in Korea, Republic of. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2014-11-04.

Sponsored by Hoffmann-La Roche · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
40
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 63 studies testing rituximab in Arthritis, Rheumatoid — 5 open to participants now, 6 under way, 1 of them phase 3. Rituximab · Arthritis, Rheumatoid.

Enrollment
51st of 63
40 · median 159
Started
2007
with 10 others
Phase 4
14 of 63
3 open now
Registered
13th of 63
by date
Lead sponsor
20 of 63
Hoffmann-La Roche

Among the 63 studies testing rituximab in Arthritis, Rheumatoid, this one is the 51st largest by enrollment, is one of 11 that started in 2007, is one of 14 in phase 4, and was the 13th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

5 of the 63 studies testing rituximab in Arthritis, Rheumatoid are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About rituximab

Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 63 studies testing rituximab in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

This single arm study will evaluate the efficacy and safety of MabThera in combination with methotrexate in patients with rheumatoid arthritis who have had an inadequate response to one or more anti-TNF therapies. Patients will receive MabThera 1000mg i.v. on days 1 and 15, and methotrexate (10-25mg/week p.o. or parenteral), together with methylprednisolone 100mg i.v. prior to infusion of MabThera. After week 24, eligible patients may receive re-treatment. The anticipated time on study treatment is 3-12 months, and the target sample size is \<100 individuals.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • adult patients, 18-80 years of age;
  • rheumatoid arthritis for >=6 months;
  • receiving outpatient treatment;
  • an inadequate response to at least one anti-TNF therapy;
  • stable methotrexate for >=12 weeks.

Exclusion criteria

Exclusion Criteria:

  • other rheumatic disease or inflammatory joint disease;
  • previous treatment with MabThera;
  • concurrent treatment with any DMARD (apart from methotrexate), anti-TNF alpha therapy, or other biologic agent.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Rituximab, Methotrexate

    Participants received rituximab 1000 milligrams (mg), intravenously (IV), on Day 1 and Day 15. Participants also received methylprednisolone 100 mg, IV, 30 minutes before the infusion of rituximab. Participants also received methotrexate (MTX) 10 to 25 milligrams per week (mg/week), orally (PO) or parenterally, and folate greater than or equal to (≥) 5 mg/week, PO, folate greater than or equal to (≥) 5 mg/week, PO, either as a single dose or as divided daily doses from Day 1 through Week 24. Participants also received prednisone less than or equal to (≤) 10 milligrams per day (mg/day), PO, OR equivalent corticosteroid, OR non-steroidal anti-inflammatory drugs (NSAIDs), PO, from Day 1 through Week 24. Eligible participants who completed the first 24-week course were entered into a second course.

    Drug: rituximab · Drug: Methotrexate · Drug: Corticosteroid or NSAID · Dietary Supplement: Folate

Interventions

  • 1000 mg i.v. on Days 1 and 15

    Also known as: MabThera, Rituxan

  • 10 to 25 mg/week p.o. or parenteral from Day 1 through Week 24

  • DrugCorticosteroid or NSAID

    ≤10 mg/day prednisone p.o., or equivalent corticosteroid, or NSAIDs p.o. from Day 1 through Week 24

  • Dietary supplementFolate

    ≥5 mg/week, once daily or b.i.d. from Day 1 through Week 24

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With An American College of Rheumatology 20 Percent (%) Improvement Criteria (ACR20) Response at Week 24

    ACR20 response: ≥20% improvement in tender joint count; ≥20% improvement in swollen joint count; and ≥20% improvement in at least 3 of 5 remaining ACR core measures: Patient Assessment of Pain; Patient Global Assessment of Disease Activity (PtGA); Physician Global Assessment of Disease Activity (PGA); self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ-DI\]); and either C-Reactive Protein (CRP) or erythrocyte sedimentation rate (ESR).

    Time frame: Week 24

Secondary outcomes

  1. Percentage of Participants With An American College of Rheumatology 50% Improvement Criteria (ACR50) Response at Week 24

    ACR50 response: ≥50% improvement in tender joint count; ≥50% improvement in swollen joint count; and ≥50% improvement in at least 3 of 5 remaining ACR core measures: Patient Assessment of Pain; PtGA; PGA; self-assessed disability (HAQ-DI); and either CRP or ESR.

    Time frame: Week 24

  2. Percentage of Participants With An American College of Rheumatology 70% Improvement Criteria (ACR70) Response at Week 24

    ACR70 response: ≥70% improvement in tender joint count; ≥70% improvement in swollen joint count; and ≥70% improvement in at least 3 of 5 remaining ACR core measures: Patient Assessment of Pain; PtGA; PGA; self-assessed disability (HAQ-DI); and either CRP or ESR.

    Time frame: Week 24

  3. Disease Activity Score Based on 28-Joint Count (DAS-28)

    DAS28 was calculated from the number of swollen joints and tender joints using the 28 joints count, the ESR (millimeters per hour \[mm/hr\]) and PtGA of disease activity with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity. DAS28 ≤3.2 equals (=) low disease activity, DAS28 greater than (\>)3.2 to 5.1 = moderate to high disease activity.

    Time frame: Baseline and Week 24

  4. Percentage of Participants With Change in DAS-28 From BL to Week 24 of ≥1.2

    DAS28 was calculated from the number of swollen joints and tender joints using the 28 joints count, the ESR (mm/hr) and PtGA of disease activity with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity.

    Time frame: Baseline, Week 24

  5. Percentage of Participants With DAS Response by European League Against Rheumatism (EULAR) Category at Week 24

    The percentage of participants categorized as good, moderate, or nonresponders according to the EULAR response criteria at Week 24. Participants were categorized as good responders if the intensity of their symptoms was in the "low disease activity (DAS28 less than \[\<\]3.2)" category after treatment, and their symptoms significantly decreased to \>1.2. Participants were categorized as moderate responders if the intensity of their symptoms was in the "moderate or high disease activity (DAS28 \>3.2)" category after treatment, and the symptoms significantly decreased to \>1.2; or if the intensity of their symptoms was in the "low or moderate disease activity (DAS28 \<5.1)" category, and the DAS28 score changed more than 0.6 or 1.2 or less. Participants were categorized as non-responders if they did not fall into the good or moderate categories.

    Time frame: Week 24

  6. Swollen Join Count (SJC)

    Number of swollen joints was determined by examination of 66 joints (as assessed through pressing and palpating during the physical examination) and identifying when swelling was present. The number of swollen joints was recorded on the joint assessment form at each visit as swollen or not swollen.

    Time frame: Baseline, Weeks 24 and 48

  7. Tender Joint Count (TJC)

    Number of tender joints was determined by examination of 68 joints (as assessed through pressing and palpating during the physical examination) and identifying when swelling was present. The number of tender joints was recorded on the joint assessment form at each visit as either tender or not tender.

    Time frame: Baseline, Weeks 24 and 48

  8. Patient Global Assessment of Disease Activity (VAS)

    The mean score of the symptoms of rheumatoid arthritis (RA) at Week 0 (baseline) and the change from Week 0 to Weeks 24 and 48 as assessed by participants using a 100 mm horizontal VAS, where the left endpoint indicated "No disease activity" (no symptom, or no symptom of RA), and the right endpoint indicated "Maximum disease activity" (maximum RA activity). A negative change from Baseline indicated improvement.

    Time frame: Baseline, Weeks 24 and 48

  9. Physician Global Assessment of Disease Activity (VAS)

    The mean score of the symptoms of RA at Week 0 and the change from Week 0 (baseline) to Weeks 24 and 48 as assessed by investigators using a 100-mm horizontal VAS, where the left endpoint indicated "No disease activity" (no symptom, or no symptom of RA), and the right endpoint indicated "Maximum disease activity" (maximum RA activity). A negative change from Baseline indicated improvement.

    Time frame: Baseline, Weeks 24 and 48

  10. Patient Assessment of Pain (VAS)

    The mean score of pain at Week 0 (baseline) and the change from Week 0 to Weeks 24 and 48 as assessed by participants using a 100-mm horizontal VAS, where the left endpoint indicated "No pain," and the right endpoint indicated "Unbearable pain." A negative change indicated improvement.

    Time frame: Baseline, Weeks 24 and 48

  11. C-reactive Protein (CRP) Level

    The mean level of CRP in milligrams per liter (mg/L), an acute phase reactant, at Week 0 and the change from Week 0 to Weeks 24 and 48.

    Time frame: Baseline, Weeks 24 and 48

  12. Erythrocyte Sedimentation Rate (ESR)

    The mean level of ESR (in mm/hr), an acute phase reactant, at Week 0 and the change from Week 0 to Weeks 24 and 48.

    Time frame: Baseline, Weeks 24 and 48

  13. HAQ-DI Score

    HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.

    Time frame: Baseline, Weeks 24 and 48

  14. Physical Function as Assessed by Short Form 36 (SF-36)

    SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).

    Time frame: Screening, Weeks 24 and 48

  15. SF-36 Mental Component Scores

    SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).

    Time frame: Screening, Weeks 24 and 48

  16. Modified Total Sharp-Genant Score (mTSS)

    Posterior-anterior (PA) radiograph of each hand and anterior-posterior (AP) radiograph of each foot were taken separately and assessed according to Genant's method as modified from Sharp's method. The Sharp-Genant score=total of the erosion score and the joint space narrowing (JSN) score of all the hands and feet. Erosion Score: 14 locations in each hand and wrist and 6 joints in the foot were evaluated for erosion using an 8-point scale where 0=Normal to 3.5=very severe erosion. JSN Score:13 locations in each hand and wrist and 6 joints in the foot were evaluated for joint narrowing score using a 9-point scale where 0=Normal to 4.0=definite ankylosis (stiffness or fixation of a joint). Maximum total erosion score in hands=100 and in feet=42; maximum scores for JSN in the hands=100 and in feet=48. Maximum modified Sharp score achievable is 290. A lower number change from Baseline indicated a better score. Change in scores was calculated as change=final score minus initial score.

    Time frame: Screening and Weeks 24 and 48

  17. Modified Sharp Radiographic Erosion Score (ES)

    Erosion Score: A total of 14 locations in each hand and wrist and 6 joints in the foot were evaluated for erosion using an 8-point scale where 0=Normal to 3.5=very severe erosion. Maximum total erosion score in the hands was 100 and in the feet was 42, for a maximum overall score of 142. Total erosion score was for both hands and feet.

    Time frame: Screening, Weeks 24 and 48

  18. Modified Sharp Radiographic Joint Space Narrowing Score (JSN)

    JSN Score: A total of 13 locations in each hand and wrist and 6 joints in the foot were evaluated for joint narrowing score using a 9-point scale where 0=Normal to 4.0=definite ankylosis (stiffness or fixation of a joint). Maximum total scores for JSN in the hands was 100 and in the feet was 48, for a maximum overall score of 148. Total JSN was for both hands and feet.

    Time frame: Screening, Weeks 24 and 48

07

Results

Posted Nov 4, 2014

Participant flow

Participant flow — Overall Study
MilestoneRituximab, Methotrexate
Started40
Completed first course38
Completed37
Not completed3
Withdrew: Withdrawal by subject2
Withdrew: Did not complete second course1

Outcome measures

PrimaryPercentage of Participants With An American College of Rheumatology 20 Percent (%) Improvement Criteria (ACR20) Response at Week 24

ACR20 response: ≥20% improvement in tender joint count; ≥20% improvement in swollen joint count; and ≥20% improvement in at least 3 of 5 remaining ACR core measures: Patient Assessment of Pain; Patient Global Assessment of Disease Activity (PtGA); Physician Global Assessment of Disease Activity (PGA); self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ-DI\]); and either C-Reactive Protein (CRP) or erythrocyte sedimentation rate (ESR).

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With An American College of Rheumatology 20 Percent (%) Improvement Criteria (ACR20) Response at Week 24
percentage of participantsRituximab, Methotrexate
Percentage of Participants With An American College of Rheumatology 20 Percent (%) Improvement Criteria (ACR20) Response at Week 2447.5 (31.5 to 63.9)
SecondaryPercentage of Participants With An American College of Rheumatology 50% Improvement Criteria (ACR50) Response at Week 24

ACR50 response: ≥50% improvement in tender joint count; ≥50% improvement in swollen joint count; and ≥50% improvement in at least 3 of 5 remaining ACR core measures: Patient Assessment of Pain; PtGA; PGA; self-assessed disability (HAQ-DI); and either CRP or ESR.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With An American College of Rheumatology 50% Improvement Criteria (ACR50) Response at Week 24
percentage of participantsRituximab, Methotrexate
Percentage of Participants With An American College of Rheumatology 50% Improvement Criteria (ACR50) Response at Week 247.5 (1.6 to 20.4)
SecondaryPercentage of Participants With An American College of Rheumatology 70% Improvement Criteria (ACR70) Response at Week 24

ACR70 response: ≥70% improvement in tender joint count; ≥70% improvement in swollen joint count; and ≥70% improvement in at least 3 of 5 remaining ACR core measures: Patient Assessment of Pain; PtGA; PGA; self-assessed disability (HAQ-DI); and either CRP or ESR.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With An American College of Rheumatology 70% Improvement Criteria (ACR70) Response at Week 24
percentage of participantsRituximab, Methotrexate
Percentage of Participants With An American College of Rheumatology 70% Improvement Criteria (ACR70) Response at Week 245.0 (0.6 to 16.9)
SecondaryDisease Activity Score Based on 28-Joint Count (DAS-28)

DAS28 was calculated from the number of swollen joints and tender joints using the 28 joints count, the ESR (millimeters per hour \[mm/hr\]) and PtGA of disease activity with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity. DAS28 ≤3.2 equals (=) low disease activity, DAS28 greater than (\>)3.2 to 5.1 = moderate to high disease activity.

Time frame:
Baseline and Week 24
Reported as:
Mean · scores on a scale
Disease Activity Score Based on 28-Joint Count (DAS-28)
scores on a scaleRituximab, Methotrexate
Week 06.76 ± 1.02
Week 245.31 ± 1.16
Change at Week 24-1.45 ± 0.94
SecondaryPercentage of Participants With Change in DAS-28 From BL to Week 24 of ≥1.2

DAS28 was calculated from the number of swollen joints and tender joints using the 28 joints count, the ESR (mm/hr) and PtGA of disease activity with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity.

Time frame:
Baseline, Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With Change in DAS-28 From BL to Week 24 of ≥1.2
percentage of participantsRituximab, Methotrexate
Percentage of Participants With Change in DAS-28 From BL to Week 24 of ≥1.260.0
SecondaryPercentage of Participants With DAS Response by European League Against Rheumatism (EULAR) Category at Week 24

The percentage of participants categorized as good, moderate, or nonresponders according to the EULAR response criteria at Week 24. Participants were categorized as good responders if the intensity of their symptoms was in the "low disease activity (DAS28 less than \[\<\]3.2)" category after treatment, and their symptoms significantly decreased to \>1.2. Participants were categorized as moderate responders if the intensity of their symptoms was in the "moderate or high disease activity (DAS28 \>3.2)" category after treatment, and the symptoms significantly decreased to \>1.2; or if the intensity of their symptoms was in the "low or moderate disease activity (DAS28 \<5.1)" category, and the DAS28 score changed more than 0.6 or 1.2 or less. Participants were categorized as non-responders if they did not fall into the good or moderate categories.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With DAS Response by European League Against Rheumatism (EULAR) Category at Week 24
percentage of participantsRituximab, Methotrexate
Good responders5.0
Moderate responders65.0
Nonresponders30.0
SecondarySwollen Join Count (SJC)

Number of swollen joints was determined by examination of 66 joints (as assessed through pressing and palpating during the physical examination) and identifying when swelling was present. The number of swollen joints was recorded on the joint assessment form at each visit as swollen or not swollen.

Time frame:
Baseline, Weeks 24 and 48
Reported as:
Mean · swollen joints
Swollen Join Count (SJC)
swollen jointsRituximab, Methotrexate
Week 016.3 ± 8.4
Change at Week 24-8.9 ± 6.2
Change at Week 48-11.6 ± 7.2
SecondaryTender Joint Count (TJC)

Number of tender joints was determined by examination of 68 joints (as assessed through pressing and palpating during the physical examination) and identifying when swelling was present. The number of tender joints was recorded on the joint assessment form at each visit as either tender or not tender.

Time frame:
Baseline, Weeks 24 and 48
Reported as:
Mean · tender joints
Tender Joint Count (TJC)
tender jointsRituximab, Methotrexate
Week 021.9 ± 14.0
Change at Week 24-9.0 ± 9.3
Change at Week 48-13.9 ± 11.1
SecondaryPatient Global Assessment of Disease Activity (VAS)

The mean score of the symptoms of rheumatoid arthritis (RA) at Week 0 (baseline) and the change from Week 0 to Weeks 24 and 48 as assessed by participants using a 100 mm horizontal VAS, where the left endpoint indicated "No disease activity" (no symptom, or no symptom of RA), and the right endpoint indicated "Maximum disease activity" (maximum RA activity). A negative change from Baseline indicated improvement.

Time frame:
Baseline, Weeks 24 and 48
Reported as:
Mean · mm
Patient Global Assessment of Disease Activity (VAS)
mmRituximab, Methotrexate
Week 072.6 ± 21.6
Change at Week 24-20.5 ± 25.8
Change at Week 48-31.8 ± 26.9
SecondaryPhysician Global Assessment of Disease Activity (VAS)

The mean score of the symptoms of RA at Week 0 and the change from Week 0 (baseline) to Weeks 24 and 48 as assessed by investigators using a 100-mm horizontal VAS, where the left endpoint indicated "No disease activity" (no symptom, or no symptom of RA), and the right endpoint indicated "Maximum disease activity" (maximum RA activity). A negative change from Baseline indicated improvement.

Time frame:
Baseline, Weeks 24 and 48
Reported as:
Mean · mm
Physician Global Assessment of Disease Activity (VAS)
mmRituximab, Methotrexate
Week 072.8 ± 13.4
Change at Week 24-30.4 ± 24.1
Change at Week 48-42.1 ± 23.0
SecondaryPatient Assessment of Pain (VAS)

The mean score of pain at Week 0 (baseline) and the change from Week 0 to Weeks 24 and 48 as assessed by participants using a 100-mm horizontal VAS, where the left endpoint indicated "No pain," and the right endpoint indicated "Unbearable pain." A negative change indicated improvement.

Time frame:
Baseline, Weeks 24 and 48
Reported as:
Mean · mm
Patient Assessment of Pain (VAS)
mmRituximab, Methotrexate
Week 069.3 ± 20.7
Change at Week 24-16.8 ± 26.1
Change at Week 48-28.2 ± 26.8
SecondaryC-reactive Protein (CRP) Level

The mean level of CRP in milligrams per liter (mg/L), an acute phase reactant, at Week 0 and the change from Week 0 to Weeks 24 and 48.

Time frame:
Baseline, Weeks 24 and 48
Reported as:
Mean · mg/L
C-reactive Protein (CRP) Level
mg/LRituximab, Methotrexate
Week 03.80 ± 4.32
Change at Week 24-1.54 ± 3.85
Change at Week 48-2.23 ± 3.01
SecondaryErythrocyte Sedimentation Rate (ESR)

The mean level of ESR (in mm/hr), an acute phase reactant, at Week 0 and the change from Week 0 to Weeks 24 and 48.

Time frame:
Baseline, Weeks 24 and 48
Reported as:
Mean · mm/hr
Erythrocyte Sedimentation Rate (ESR)
mm/hrRituximab, Methotrexate
Week 077.2 ± 28.6
Change at Week 24-23.4 ± 27.1
Change at Week 48-36.1 ± 26.0
SecondaryHAQ-DI Score

HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.

Time frame:
Baseline, Weeks 24 and 48
Reported as:
Mean · scores on a scale
HAQ-DI Score
scores on a scaleRituximab, Methotrexate
Week 01.66 ± 0.70
Change at Week 24-0.34 ± 0.58
Change at Week 48-0.53 ± 0.64
SecondaryPhysical Function as Assessed by Short Form 36 (SF-36)

SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).

Time frame:
Screening, Weeks 24 and 48
Reported as:
Mean · scores on a scale
Physical Function as Assessed by Short Form 36 (SF-36)
scores on a scaleRituximab, Methotrexate
Screening, Physical functioning (n=39)27.7 ± 17.2
Screening, Role-physical (n=39)26.6 ± 21.5
Screening, Bodily pain (n=39)29.2 ± 17.5
Screening, General health (n=39)31.7 ± 16.2
Week 24, Physical functioning (n=39)35.8 ± 22.5
Week 24, Role-physical (n=39)41.5 ± 23.1
Week 24, Bodily pain (n=39)44.7 ± 19.7
Week 24, General health (n=39)38.1 ± 17.1
Week 48, Physical functioning (n=39)43.4 ± 26.7
Week 48, Role-physical (n=38)49.3 ± 29.0
Week 48, Bodily pain (n=38)50.9 ± 22.7
Week 48, General health (n=38)44.9 ± 22.7
SecondarySF-36 Mental Component Scores

SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).

Time frame:
Screening, Weeks 24 and 48
Reported as:
Mean · scores on a scale
SF-36 Mental Component Scores
scores on a scaleRituximab, Methotrexate
Screening, Vitality (n=38)30.3 ± 18.6
Screening, Social functioning (n=39)41.7 ± 26.8
Screening, Role-emotional (n=39)36.8 ± 25.3
Screening, Mental health (n=38)52.9 ± 19.5
Week 24, Vitality (n=39)35.7 ± 21.2
Week 24, Social functioning (n=39)55.5 ± 25.6
Week 24, Role-emotional (n=39)53.9 ± 27.6
Week 24, Mental health (n=39)56.0 ± 21.4
Week 48, Vitality (n=38)44.2 ± 26.6
Week 48, Social functioning (n=38)63.2 ± 26.0
Week 48, Role-emotional (n=38)55.5 ± 31.9
Week 48, Mental health (n=38)60.7 ± 23.9
SecondaryModified Total Sharp-Genant Score (mTSS)

Posterior-anterior (PA) radiograph of each hand and anterior-posterior (AP) radiograph of each foot were taken separately and assessed according to Genant's method as modified from Sharp's method. The Sharp-Genant score=total of the erosion score and the joint space narrowing (JSN) score of all the hands and feet. Erosion Score: 14 locations in each hand and wrist and 6 joints in the foot were evaluated for erosion using an 8-point scale where 0=Normal to 3.5=very severe erosion. JSN Score:13 locations in each hand and wrist and 6 joints in the foot were evaluated for joint narrowing score using a 9-point scale where 0=Normal to 4.0=definite ankylosis (stiffness or fixation of a joint). Maximum total erosion score in hands=100 and in feet=42; maximum scores for JSN in the hands=100 and in feet=48. Maximum modified Sharp score achievable is 290. A lower number change from Baseline indicated a better score. Change in scores was calculated as change=final score minus initial score.

Time frame:
Screening and Weeks 24 and 48
Reported as:
Mean · scores on a scale
Modified Total Sharp-Genant Score (mTSS)
scores on a scaleRituximab, Methotrexate
Screening79.5 ± 48.5
Change at Week 240.26 ± 0.55
Change at Week 480.64 ± 1.16
SecondaryModified Sharp Radiographic Erosion Score (ES)

Erosion Score: A total of 14 locations in each hand and wrist and 6 joints in the foot were evaluated for erosion using an 8-point scale where 0=Normal to 3.5=very severe erosion. Maximum total erosion score in the hands was 100 and in the feet was 42, for a maximum overall score of 142. Total erosion score was for both hands and feet.

Time frame:
Screening, Weeks 24 and 48
Reported as:
Mean · scores on a scale
Modified Sharp Radiographic Erosion Score (ES)
scores on a scaleRituximab, Methotrexate
Screening25.2 ± 25.1
Change at Week 240.18 ± 0.42
Change at Week 480.49 ± 0.89
SecondaryModified Sharp Radiographic Joint Space Narrowing Score (JSN)

JSN Score: A total of 13 locations in each hand and wrist and 6 joints in the foot were evaluated for joint narrowing score using a 9-point scale where 0=Normal to 4.0=definite ankylosis (stiffness or fixation of a joint). Maximum total scores for JSN in the hands was 100 and in the feet was 48, for a maximum overall score of 148. Total JSN was for both hands and feet.

Time frame:
Screening, Weeks 24 and 48
Reported as:
Mean · scores on a scale
Modified Sharp Radiographic Joint Space Narrowing Score (JSN)
scores on a scaleRituximab, Methotrexate
Screening54.3 ± 27.6
Change at Week 240.08 ± 0.24
Change at Week 480.15 ± 0.51

Adverse events

Collected over Adverse events (AEs) were reported from Screening up through Week 48 or Withdrawal Visit.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rituximab, Methotrexate—6/40 (15%)38/40 (95%)
Most frequent serious events
Most frequent serious events
EventRituximab, Methotrexate
AppendicitisGastrointestinal disorders2/40
Arthritis bacterialInfections and infestations1/40
InfectionInfections and infestations1/40
Scrub typhusInfections and infestations1/40
ConcussionInjury, poisoning and procedural complications1/40
Knee arthroplastySurgical and medical procedures1/40
Most frequent other events
Showing 10 of 65
Most frequent other events
EventRituximab, Methotrexate
Upper respiratory tract infectionInfections and infestations12/40
RashSkin and subcutaneous tissue disorders6/40
ArthralgiaMusculoskeletal and connective tissue disorders5/40
Feeling hotGeneral disorders4/40
Pharyngolaryngeal painRespiratory, thoracic and mediastinal disorders4/40
OnychomycosisInfections and infestations3/40
MyalgiaMusculoskeletal and connective tissue disorders3/40
Rheumatoid arthritisMusculoskeletal and connective tissue disorders3/40
AlopeciaSkin and subcutaneous tissue disorders3/40
PruritusSkin and subcutaneous tissue disorders3/40

Baseline characteristics

Intent to treat (ITT) population included all enrolled participants who received the investigational treatment.

Age, Continuous
Age, Continuous(years)Rituximab, Methotrexate
Mean49.9 ± 11.4
Sex: Female, Male
Sex: Female, Male(Participants)Rituximab, Methotrexate
Female34
Male6
08

Study locations

4 sites
  • Seoul, 110-744, Korea, Republic of
  • Seoul, 133-792, Korea, Republic of
  • Seoul, 137701, Korea, Republic of
  • Seoul, 138-736, Korea, Republic of
09

References and documents

Publications

  • Vieira MC, Zwillich SH, Jansen JP, Smiechowski B, Spurden D, Wallenstein GV. Tofacitinib Versus Biologic Treatments in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors: Results From a Network Meta-analysis. Clin Ther. 2016 Dec;38(12):2628-2641.e5. doi: 10.1016/j.clinthera.2016.11.004. Epub 2016 Nov 24. PubMed 27889300 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2007, a primary completion of Jul 2009 and a completion of Jul 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2014, 5 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 18, 2007
First posted
Apr 19, 2007
Start
Jun 2007
Primary completionActual
Jul 2009
CompletionActual
Jul 2009
Results first posted
Nov 4, 2014
Last update
Nov 4, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 4, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00462345
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Apr 19, 2007
Start date
Jun 2007
Primary completion
Jul 2009
Completion
Jul 2009
Results posted
Nov 4, 2014
Last update
Nov 4, 2014

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Rituximab · Methotrexate

Start the discussion